Arcellx (ACLX) Income from Continuing Operations (2021 - 2025)
Arcellx's (ACLX) quarterly Income from Continuing Operations came in at 58024000.0 in Q4 2025, down 23.34% year-on-year from 75687325.46 in Q4 2024, and down 4.02% quarter-over-quarter from 55781000.0 in Q3 2025.
Arcellx (ACLX) Income from Continuing Operations (2021 - 2025) Analysis & Trends
Arcellx's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 58024000.0 for Q4 2025.
- On a quarterly basis, Income from Continuing Operations fell 23.34% year-over-year to 58024000.0 in Q4 2025; TTM through Dec 2025 was 228846000.0, a 113.33% decrease from a year earlier, with the FY2025 full-year figure at 228846000.0, down 113.18% from the prior year.
- Income from Continuing Operations slipped to 58024000.0 in Q4 2025 per ACLX's latest filing, from 55781000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 19844000.0 in Q4 2023 and bottomed at 92874000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 29058000.0 (2022), against an average of 34961550.0.
- Across the five-year window, Income from Continuing Operations surged 150.89% in 2023 and tumbled 765.1% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 59438000.0 in 2021, then soared by 34.4% to 38992000.0 in 2022, then jumped by 150.89% to 19844000.0 in 2023, then slumped by 337.07% to 47045000.0 in 2024, then retreated by 23.34% to 58024000.0 in 2025.
- Per Business Quant, the three latest ACLX Income from Continuing Operations figures stand at 58024000.0 (Q4 2025), 55781000.0 (Q3 2025), and 52771000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | -58.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -58.02 Mn |
| Sep 30, 2025 | -55.78 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | -62.27 Mn |
| Dec 31, 2024 | -47.05 Mn |
| Sep 30, 2024 | -25.87 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -7.20 Mn |
| Dec 31, 2023 | 19.84 Mn |
| Sep 30, 2023 | -39.34 Mn |
| Jun 30, 2023 | -23.84 Mn |
| Mar 31, 2023 | -27.34 Mn |
| Dec 31, 2022 | -38.99 Mn |
| Sep 30, 2022 | -92.87 Mn |
| Jun 30, 2022 | -30.77 Mn |
| Mar 31, 2022 | -26.04 Mn |
| Dec 31, 2021 | -59.44 Mn |
| Sep 30, 2021 | -17.12 Mn |
| Jun 30, 2021 | -15.93 Mn |
| Mar 31, 2021 | -11.28 Mn |